Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

Summary

This study is designed to explore the efficacy and safety of Telitacicept combined with low-dose steroids for the treatment of refractory MG, and to investigate related biomarkers such as immunoglobulins, BlyS/APRIL, and AChR-Ab titers, in order to clarify whether Telitacicept can rapidly and effectively help achieve MG treatment goals and assist in steroid reduction.

Timeline

Start

2024-12

Primary completion

2025-12

Completion

2026-12

Drugs

Indications